Bid of DKK 16.5/share is a ~110% premium to last close Several major shareholders intend to accept t...
The positive results in Nanexa’s Phase I study for NEX-22, a once-monthly depot formulation of the G...
Sales SEK 49m (ABGSCe 79m), EBIT -8m (ABGSCe +1m) Slower recovery, flat sales expected in future qua...
Solwers posted Q3 results that were on the weak side on profitability versus Q3 2023.
Redeye updates its estimates following MindArk’s weaker-than-expected Q3 report.
Redeye updates its view on Verve Group following its Q3 2024 report, which showed strong growth, as ...
Warsaw Unit adds ~40% to top-line... ...and 15% to CEPS in 2025/2026e Impressive execution, share no...
Redeye gives initial comments on the acquisition by Tagmaster that was announced today.
Zoomability Int AB (”Zoomability” eller ”bolaget”) publicerade den 28 november 2024 bolagets delårsr...
Cereno Scientific has released its Q324 results, marking a productive and strategically significant ...
Embark Group AB (”Embark” eller ”Bolaget”) släppte en stark rapport för det tredje kvartalet där int...
Lipigons fas 2a-studie med triglyceridsänkaren Lipisense har inkluderat sin första patient, en vikti...
Redeye comments on Verve Group’s Q3 2024 results, which exceeded expectations in terms of sales.
Redeye comments on MindArk’s Q3 results, which were weaker than expected in both sales and profitabi...
Redeye provides a more in-depth review of AcouSort’s Q3 report, which did not include any major supr...
Prolight continues to make progress with its proprietary Psyros platform, with a pre-validation stud...
Redeye has revised its forecast following TH1NG’s Q3 2024 report, where sales declined y/y due to th...
Zoomability Int AB (”Zoomability” eller ”bolaget”) meddelade den 27 november att bolaget har testat ...
STENOCARE announced on November 26th the STENOCARE 3.
Redeye provides a brief comment on Pepaxti's market access in Italy.
